Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine—SORELLA 1 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine—SORELLA 1 Study

Published:2017-09 Issue:9 Volume:19 Page:516-526
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Garg Satish K.¹,Wernicke-Panten Karin²,Rojeski Maria³,Pierre Suzanne⁴,Kirchhein Yvonne²,Jedynasty Krystyna⁵

Affiliation:

1. Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.

2. Sanofi-aventis Deutschland GmbH, Frankfurt, Germany.

3. Sanofi, Bridgewater, New Jersey.

4. Sanofi, Paris, France.

5. Centrum Diabetologiczne, Centralny Szpital Kliniczny MSW, Warsaw, Poland.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.liebertpub.com/doi/pdf/10.1089/dia.2017.0117

Reference13 articles.

1. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus

2. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

3. Standards of Medical Care in Diabetes—2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of biosimilar insulins in 2023;Canadian Diabetes & Endocrinology Today;2023-03-20

2. An Institutional Guide for Formulary Decisions of Biosimilars;Hospital Pharmacy;2022-11-29

3. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary;Clinical Pharmacology & Therapeutics;2022-11-04

4. Biosimilar insulin concepts;Journal of Diabetes;2022-03-28

5. Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects;Clinical Pharmacology in Drug Development;2022-02-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3